MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$4,986,614
EPS
-$0.15
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
2,669,779 -3,770,856.5* 14,521,342 2,569,943
General and administrative expenses
2,406,587 2,140,941.5* 1,287,783 1,353,172
Total operating expenses
5,076,366 -1,629,915 15,809,125 3,923,115
Gain from operations
-5,076,366 1,629,915* -15,809,125 -3,923,115
Loss on debt conversion with related party
--7,078,664.75* --
Loss on fixed asset disposal
--682.75* --
Sublease income
19,455 ---
Interest income (expense), net
77,350 -191,003.5* 80,582 111,379
Exchange loss, net
-5,860 -8,450.5* -17,509 4,532
Total other income (expense)
90,945 -7,278,801.5* 63,073 115,911
Loss before income taxes
-4,985,421 -5,648,886.5* -15,746,052 -3,807,204
Deferred income tax expense
1,193 223,026.5* -1,436 149
Net loss
-4,986,614 -5,871,913* -15,744,616 -3,807,353
Accrual of paid-in-kind dividends on series a non-voting convertible preferred stock
--314,165.5* --
Net loss attributable to common stockholders
-4,986,614 -6,186,078.5 -15,744,616 -3,807,353
Basic EPS
-0.15 -0.557 -8.2 -1.99
Diluted EPS
-0.15 -0.557 -8.2 -1.99
Basic Average Shares
33,544,748 11,101,777 1,919,433 1,911,128
Diluted Average Shares
33,544,748 11,101,777 1,919,433 1,911,128
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$4,986,614 Net loss-$4,986,614 Interest income(expense), net$77,350 Sublease income$19,455 Loss before incometaxes-$4,985,421 Deferred income taxexpense$1,193 Total other income(expense)$90,945 Exchange loss, net-$5,860 Gain from operations-$5,076,366 Total operatingexpenses$5,076,366 Research and development$2,669,779 General andadministrative expenses$2,406,587

Dogwood Therapeutics, Inc. (DWTX)

Dogwood Therapeutics, Inc. (DWTX)